Retaglutide and tirzepatide represent cutting-edge class of medications known as dual GLP-1 and GIP agonists. These agents target both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide https://bookmarkshome.com/story6448604/novel-glp-1-and-gip-agonists-retaglutide-and-tirzepatide-for-type-2-diabetes